BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Journal for ImmunoTherapy of Cancer / Sep 22, 2022
Poster Presentation With Sanofi presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
ASCO 2022 Annual Meeting
BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models
Poster Presentations at AACR 2020 Virtual Annual Meeting
Biond Biologics to Attend the Jefferies 2019 London Healthcare Conference
18th National Life Sciences & Technology Week May 14 – 16, 2019 | David InterContinental Tel Aviv, Israel.
Biond Biologics to Attend the J.P. Morgan 38th Annual Healthcare Conference (JPM 2020)
J.P. Morgan 38th Annual Healthcare Conference (JPM 2020) January 13 – 16, 2020 | San Francisco, CA, USA.
MIXiii-BIOMED 2019
18th National Life Sciences & Technology Week May 14 – 16, 2019 / David InterContinental Tel Aviv, Israel.
MIXiii-BIOMED 2018
17th National Life Sciences & Technology Week, May 15 – 17, 2018 } David InterContinental Tel Aviv, Israel.
Biond Biologics to Attend the J.P. Morgan 41st Annual Healthcare Conference (JPM 2023)
J.P. Morgan 41st Annual Healthcare Conference (JPM 2023) January 9 – 12, 2023 | San Francisco, CA, USA.
Biond Biologics to Attend 19th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society
19th Annual Meeting of The Medicinal Chemistry Section of the Chemical Society Biomed Israel, Weizmann Institute of Science, Rehovot, Israel | July 20th, 2023
Biond Biologics to Present at the 2nd Immuno-oncological Meeting of the Israel Immunological Society (IIS) 2022
2nd Immuno-Oncological Meeting of the Israel Immunological Society (2022) February 22-24, 2022| Haifa, Israel